Brought to you by 
SV Life Sciences leads Juvaris's $25mm Series B
23 Sep 2009
Executive Summary
Juvaris BioTherapeutics (adjuvant vaccines for infectious diseases) announced its $25mm Series B financing round led by first-time backer SV Life Sciences, which was joined by returning shareholder Kleiner Perkins Caufield & Byers. The company will use the money to continue developing its platform of cationic-lipid DNA complexes, including lead clinical candidate JVRS100 for seasonal and pandemic influenza. A member of SV Life Sciences takes a seat on the board.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SV Life Sciences leads Juvaris's $25mm Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice